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ABSTRACT: 
Excessive blood vessel formation in the eye is implicated in wet age-related macular 
degeneration, proliferative diabetic retinopathy, neovascular glaucoma and retinopathy of 
prematurity, which are major causes of blindness. Small molecule antiangiogenic drugs are 
strongly needed to supplement existing biologics. Homoisoflavonoids have been previously 
shown to have potent anti-proliferative activities in endothelial cells over other cell types. 
Moreover, they demonstrated a strong antiangiogenic potential in vitro and in vivo in animal 
models of ocular neovascularization. Here, we tested the antiangiogenic activity of a group of 
naturally occurring homoisoflavonoids isolated from the family Hyacinthaceae and related 
synthetic compounds, chosen for synthesis based on structure activity relationship 
observations. Several compounds showed interesting anti-proliferative and antiangiogenic 
activities in vitro on retinal microvascular endothelial cells, a disease-relevant cell type, with 
the synthetic chromane, 46, showing the best activity (GI50 of 2.3 x 10
-4 µM).
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Abnormal formation of new blood vessels in the eye is associated with blindness in many 
ocular diseases such as retinopathy of prematurity (ROP) affecting children, proliferative 
diabetic retinopathy (PDR), the wet form of age-related macular degeneration (AMD) and 
neovascular glaucoma affecting adults, and elderly people, respectively.1 The newly formed 
vasculature is fragile and leaky causing hemorrhage and accumulation of fluids in the retina. If 
left untreated, the resulting edema and fibrotic scarring can lead to irreversible vision loss.2 
The current pharmacotherapeutic mainstays for these diseases are biologics targeting the 
vascular endothelial growth factor (VEGF) such as bevacizumab, ranibizumab, and 
aflibercept.3 Despite being successful in suppressing disease progression, these large molecule 
therapies are associated with some undesirable ocular and systemic side effects as well as the 
time consuming regular visits to hospitals required for the intravitreal injections.4,5 Moreover, 
resistance is a problem: about 30% of wet AMD patients are resistant to these biologics.6  
Currently, there is no FDA approved small molecule for the treatment of ocular 
neovascularization. Therefore, there is an unmet need to develop novel and specific anti-
angiogenic small molecule therapies to complement and combine with existing drugs for ROP, 
PDR, and wet AMD.  
Natural products continue to provide appealing lead compounds for treatment of diseases.7 
Naturally occurring homoisoflavonoids are reported to have diverse biological activities 
including antioxidant, anti-inflammatory and antiangiogenic activities.8 The Hyacinthaceae is 
one of the families rich in homoisoflavonoids distributed in different parts of the plants. The 
Hyacinthaceae (sensu APGII) consists of approximately 900 species, in about 70 genera. The 
family can be divided into four subfamilies, the widespread Hyacinthoideae, Urgineoideae and 
Ornithogaloideae and the small sub-family Oziroëoideae which is restricted to South America. 
For the most part, the compounds found are sub-family restricted. Homoisoflavonoids and 
spirocyclic nortriterpenoids characterise the Hyacinthoideae, bufadienolides the Urgineoideae 
and cardenolides and steroidal glycosides the Ornithogaloideae. To date, no phytochemical 
investigations have been reported of the Oziroëoideae.9 
Members of the Hyacinthoideae subfamily have a long tradition of being used by traditional 
healers to treat a wide range of complaints. Phytochemical investigations of the genus Eucomis 
L’Hér.,10 Ledebouria revoluta (L.F.) Jessop,11 Ledebouria ovatifolia (Baker) Jessop,12 
Merwilla plumbea (Lindl.) Speta13 all widely used in African traditional medicine, have been 
reported. 
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Previously, a homoisoflavanone, cremastranone, isolated from the orchid Cremastra 
appendiculata (D.Don) Makino, was shown to have antiangiogenic activity in the ocular 
context, but unfortunately, the configuration at C-3 was not reported.14-16 This compound was 
also previously isolated from the Hyacinthoideae genera Muscari Mill.,17 and Merwilla Speta.13  
More recently, a synthetic racemate of this compound showed strong antiangiogenic activity 
against human retinal microvascular endothelial cells (HRECs), with lesser effects on non-
endothelial cell types.18 A synthetic regioisomer of cremastranone (SH-11052) also had 
antiangiogenic activities in vitro.19 Subsequently, our SAR campaign identified a promising 
synthetic analogue of cremastranone, named SH-11037, with more potent and selective 
antiproliferative effects on HRECs compared to endothelial cells of macrovascular origin.20 
Moreover, SH-11037 demonstrated strong antiangiogenic potential in vivo in animal models 
of ROP20 and choroidal neovascularization.21 We have also isolated known and novel 
homoisoflavonoids from Massonia Houtt. species, some of which showed selective 
antiproliferative effects on HRECs.22 Given the selective and potent antiangiogenic activity of 
cremastranone and derivatives, the search for further antiangiogenic homoisoflavonoids is 
warranted. In parallel with our medicinal chemistry approach,20 we have here further explored 
natural-source and related synthetic homoisoflavonoids as antiangiogenic agents.  
Homoisoflavonoids and related compounds isolated from seven species of Hyacinthaceae have 
been investigated in this study for antiangiogenic activity. The isolation and structure 
determination of compounds from Ledebouria socialis (Baker) Jessop (1, 2), Ledebouria 
ovatifolia (Baker) Jessop (3-14), Rhodocodon campanulatus Knirsch (25, 26), Mart-Azorín 
and Wetschnig, Rhodocodon aff. intermedius Knirsch, Mart-Azorín and Wetschnig (27-29), 
have been reported by us previously and compounds from these sources were screened as part 
of this work.23,24 In addition, Chionodoxa luciliae Boiss, Eucomis autumnalis (Mill.) Chitt. and 
Eucomis bicolor Baker were re-investigated to provide material for screening and a previously 
unreported homoisoflavonoid, 35, along with previously reported ones were isolated, some for 
the first time from these sources.  These species were chosen for re-extraction due to large 
amounts of bulb material being available from a commercial supplier enabling us to isolate 
large amounts of compounds for screening purposes. 
In addition, based on our cell-based structure-activity observations, a number of known (44, 
47, 48) and previously undescribed homoisoflavonoids (42, 43, 45, 46, 49 and 50) were 
synthesized and investigated for antiangiogenic activity, including the enantioselective 
synthesis of compound 45 with the 3R configuration.  Compound 46, a previously undescribed 
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compound with a chromane skeleton, showed significantly greater activity than the related 
chromanones (45 and 47). 
RESULTS AND DISCUSSION  
The EtOH extract of the bulbs of Chionodoxa luciliae Boiss yielded compound 16, para-
hydroxybenzaldehyde, and homoisoflavonoids 15, 17 and 21-24.  Compound 17 was acetylated 
and yielded the 7-acetate (19) and 3,7-diacetate (20). Compound 16 is likely to be a degradation 
product of compound 21. All compounds have been reported previously from several 
sources9,25 but this is the first report of the isolation of compounds 17, 22 and 23 from a 
Chionodoxa species. Structures were determined using NMR techniques and were confirmed 
by comparison against literature data; the configurations at C-3 were confirmed using circular 
dichroism spectroscopy and optical rotation measurements.  
The MeOH and butanol extracts of the bulbs of Eucomis autumnalis yielded compounds 22 
and 30-39 and the EtOH extract of the bulbs of E. bicolor yielded compounds 40 and 41.  
Compounds 31 and 32 have been isolated previously from both E. autumnalis and E. bicolor,26 
compound 36 from E. autumnalis,27,28,29 compounds 30, 40 and 41 from E. bicolor,27,30,31 
compound 33 from E. montana,32 compound 38 from Muscari armeniacum,17 compound 39 
from Scilla persica33 and compound 37 from Ledebouria ovatifolia.23 
Compound 35, 3R-(4ʹ-hydroxybenzyl)-6,8-dihydroxy-5,7-dimethoxy-4-chromanone, is a 
homoisoflavonoid that has not been reported previously with a fully substituted ring A. HRMS 
showed a protonated molecular ion at m/z 347.11254 corresponding to a molecular formula of 
C18H18O7.  Characteristic peaks at δH 4.37 (H-2α, dd, 11.4, 4.1 Hz), δH 4.20 (H-2β, dd, 11.4, 7.2 
Hz), 2.79 (H-3, m), δH 3.17 (H-9A, dd, 14.0, 4.4 Hz) and δH 2.70 (H-9B, dd, 14.0, 10.6 Hz) 
were indicative of a 3-benzyl-4-chromanone structure and resonances at δH 6.79 (2H, 3ʹ,5ʹ, 8.1 
Hz) and δH 7.11 (2H, 2ʹ and 6ʹ, 8.1 Hz) showed that the B ring was para- disubstituted.  The 
two H-2 and two H-9 resonances showed correlations with the C-4 keto group carbon 
resonance at δC 192.0.  Two methoxy group proton resonances and three exchangeable hydroxy 
group proton resonances (δH 5.59, 6-OH; δH 5.39, 8-OH and δH 4.74, 4ʹ-OH) could be assigned 
from correlations seen in the HMBC spectrum (Figure 1). A specific rotation of -55.6 and 
negative Cotton effect at 290 nm indicated a 3R-configuration.11 Homoisoflavonoids with a 
fully substituted ring A are rare with only two similar compounds being reported previously: 
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(4ʹ-hydroxybenzyl)-5,6-dihydroxy-7,8-dimethoxy-4-chromanone, from Bellevalia eigii 34 and 
(4ʹ-hydroxy)-5,8-dihydroxy-6,7-dimethoxy-4-chromanone, from Muscari comosum.35   
Previous work on synthetic analogues of cremastranone demonstrated that much potential 
remained for the improvement of activity. Previously, 3-benzyl analogues had been synthesised 
as racemic mixtures and we wished to investigate the possibility of synthesising a single 
enantiomer via selective hydrogenation of the 3,9-double bond of a 3-benzylidene analogue. In 
addition, the effect of producing the chromane derivative of 5,6,7-trimethoxy-3-(3ʹ-hydroxy-
4ʹ-methoxybenzylidene)-4-chromanone was of interest. Homoisoflavonoids 42 to 49 were 
synthesised following known methods36 (Schemes 1 and 2). An iridium catalyst, the (S)-4-tert-
butyl-2-[2-(diphenylphosphino)phenyl]-2-oxazoline complex, also known as iridium–
phosphino-oxazoline or phox, used to hydrogenate compound 44 to form 45, was synthesised 
using known methodology37 and is shown in Scheme 2.  Chalcone 50 was synthesised via a 
Claisen-Schmidt condensation, using known methods.38 
Syntheses of compounds 44, 47 and 48 have been reported 20,39 while the synthesis of 
compounds 42, 43, 45, 46, 49 and 50 has not been reported before.  Compounds 42 and 43 
were both synthesised in low yield (3 and 3.5% respectively).  The first two steps proceeded 
well, with the low yield being a result of poor reaction completion in step three and extensive 
chromatography to produce the pure product.  The structures were confirmed by high resolution 
mass spectrometry and NMR analysis. 
Compound 44 was used as a starting point for our investigation into the asymmetric 
hydrogenation of the 3,9-double bond in the benzylidene-type homoisoflavonoids using the 
iridium catalyst (Scheme 2) for the hydrogenation.  The reaction proceeded quantitatively to 
give compound 45. 
A systematic conformational search of 3R- and 3S-isomers of 5,6,7-trimethoxy-(3ʹ-hydroxy-
4ʹ-methoxybenzyl)-4-chromanone was performed via molecular mechanics force field 
calculation (MMFF) built in the software Spartan'16. Conformers under 3.0 kJ/mol relative 
energy cut-off were selected and optimised using Density Functional Theory (DFT) 
calculations at B3LYP/6-31 G + (d,p) level built into Gaussian09. Once optimised, their ECD 
spectra were simulated using Time Dependant Density Functional Theory (TDDFT) at the 
B3LYP/6-31 + G (d,p) level. A polarisable continuum model (IEFPCM) was applied during 
the TDDFT calculation to simulate the presence of acetonitrile, which was the solvent used in 
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the experimental ECD. The ECD spectra obtained for each conformer were Boltzmann 
weighted and compared to the experimental ECD spectrum of 45.40 The 6-31 + G(d,p) basis 
set was applied as it provides a fine balance between accuracy and computational time needed. 
In addition, it has been applied in the past by our group with satisfactory results.41  
The measured ECD spectrum of 45 showed a positive Cotton effect at λ (Δε) 326 (+1.3) and a 
negative Cotton effect at λ (Δε) 284 (-1.9), which is in accordance with the theoretical 
calculated spectrum for the 3R-enantiomer, indicating the 3R configuration for compound 45 
(Supporting Information).42 For comparative purposes compound 44 was hydrogenated using 
Pd/C to give the racemic mixture, 46.  This reaction resulted in the reduction of both the 3,9-
double bond as well as the carbonyl group at C-4 as shown by the loss of the fully-substituted 
carbon resonance at C 179.8 (C-4) and the new methylene resonance at C 37.5 (C-4).  
Coupling could clearly be seen in the COSY spectrum between the resonance at H 2.14 (1H, 
m, H-3) and the resonance at H 2.53 (2H, dd, J = 4.1 and 7.4 Hz, H-4).  Compound 44 was 
then successfully hydrogenated using Wilkinson’s catalyst 
(tris(triphenylphosphine)rhodium(I) chloride) to give compound 47, the previously synthesised 
racemate.20 Compound 48 was synthesised to determine whether the presence of a 5-OH group 
was significant for activity.  Many natural homoisoflavonoids have a hydroxyl group at C-5.  
The selective demethylation was confirmed by the appearance of a sharp singlet at H 12.45, 
due to the proton of a H-bonded hydroxyl group at C-5.  In addition, three methoxy groups 
were noted instead of four. 
Compound 49 was synthesised from 3,4,5-trimethoxyphenol and 4-chloro-3-
hydroxybenzaldehyde and the expected product was formed. A HRESIMS value of m/z 
377.0786 [M + H]+ indicated a molecular formula of C19H17O6Cl.  The structure of the product 
was confirmed by key 1H NMR resonances at H 4.99 (2H, d, J = 1.8 Hz, H-2), 7.75 (1H, bs, 
H-9), 6.16 (1H, s, H-8) and three methoxy group three-proton resonances at H 3.75 (3H, s), 
3.82 (3H, s) and 3.91(3H, s).  The B-ring resonances at H 7.15 (1H, dd, J = 2.4 and 8.6 Hz, H-
2ʹ), 6.91 (1H, d, J = 2.4, H-6ʹ) and 6.83 (1H, d, J = 8.6, H-3ʹ) supported the 4ʹ, 5ʹ-substitution 
pattern. 
 
Compound 50, a chalcone, was synthesised from 3,4-dimethoxybenzaldehyde and 4ʹ-ethoxy-
2ʹ-hydroxy-3ʹ-methylacetophenone via a Claisen-Schmidt condensation. The HRESIMS gave 
a [M+H]+ ion at m/z 343.1545, giving a molecular formula of C20H22O5 for the compound.  The 
8 
 
chalcone structure was confirmed by a pair of doublets in the 1H NMR spectrum at H 7.47 
(1H, d, J = 15.2 Hz, H-2) and 7.84 (1H, d, J = 15.2 Hz, H-3) indicative of E geometry. 
 
Antiproliferative activities of homoisoflavonoids 
To find novel antiangiogenic homoisoflavonoids, compounds were tested for their 
antiproliferative activities on HRECs. To assess effects on other normal cell types, we tested 
compounds against primary macrovascular human umbilical vein endothelial cells (HUVECs; 
a non-target endothelial cell type) or the retinal pigment epithelial cell line, ARPE-19, a non-
target ocular cell type. Ideal antiangiogenic candidates should have lesser effects on these non-
target cell types than on HRECs. To further assess potential cytotoxic effects against ocular 
cell types, we also employed two ocular cancer cell lines, uveal melanoma 92-1 and 
retinoblastoma Y79. Again, ideal candidates for further investigation as antiangiogenic 
homoisoflavonoids should show lower activity against these other ocular cell lines derived 
from uveal melanocytes and photoreceptor precursors, respectively. 
While many of the compounds lacked activity against the cell types, some compounds were 
reasonably potent and selective for the endothelial cell types (Tables 1 and 2; Figures 2–4).  
The results would suggest some structural features are significant in determining the activity 
of the homoisoflavonoid.  Optimal activity was observed when the A-ring was either 5,6,7-
trisubstituted or 5,7-disubstituted. If only two substituents were present, at least one of them 
would need to be an acetyl rather than a hydroxy group.  3ʹ,4ʹ -Disubstitution in ring B produced 
the highest activity, in particular when combined with the presence of a 3/9 double bond.  
Homoisoflavonoids with the bulkier 3ʹ-acetyl group were more active than ones with the 3ʹ-
hydroxyl group. The presence of a cyclobutane ring rendered the homoisoflavonoid inactive, 
regardless of the substituents on rings A and B.  The importance of a 5,6,7-trisubstituted A-
ring was confirmed by the synthetic samples, with the trisubstituted compounds (44, 45, 46, 
47, 48 and 49) showing better activity than the disubstituted compounds (42 and 43). 
Interestingly, the 3R-enantiomer (45) showed greater activity than the precursor with a double 
bond in the 3,9-position (44) as well as greater activity than the racemic mixture (47).  This 
serves to emphasise the importance of being able to synthesise these homoisoflavonoids 
enantioselectively.  The complete reduction of both the 3,9-double bond and the carbonyl group 
at C-4 produced a highly active compound (46) (Table 2, GI50 (HREC) of 2.3 x 10
-4 M, GI50 
(ARPE-19) of 3.4 x 10-4 M, and GI50 (92-1) of 52 M). This significant increase in activity 
9 
 
with the loss of the carbonyl group at C-4 has not been reported before, although this compound 
was synthesized simultaneously by the Seo lab (personal communication). Compound 49, with 
a 4ʹ-chloro-3ʹ-hydroxyphenylbenzylidene group at C-3 produced good activity with selectivity 
for HRECs (Table 2, GI50 (HREC) of 0.11 M, GI50 (92-1) of 3.6 M), compared to that of 
compound 44 (Table 2, GI50 (HREC) of 2.2 M, GI50 (92-1) of 8.2 M).  By way of 
comparison, cremastranone as reported was substantially less potent, but still selective (GI50 
(HREC) of 0.22 M, GI50 (HUVEC) of 0.38 M, GI50 (92-1) of 48 M, GI50 (Y79) of 9.8 
M).20 
In vitro antiangiogenic efficacy of the potent homoisoflavonoids 
After identifying some of the most potent anti-proliferative compounds with some selectivity 
for HRECs – compounds 13, 27, 28, 45, 46, 48, and 50– we further investigated their potential 
in inhibiting the ability of HRECs to form tubes.  Matrigel based tube formation is the gold-
standard in vitro assay that recapitulates most of the physiological angiogenesis events such as 
cell proliferation, migration, and cell-cell adhesion, as endothelial cells form three dimensional 
tube-like structures.43 Interestingly, all three of the natural-source compounds (13, 27, and 28), 
inhibited the ability of HRECs to form tubes in a concentration-dependent manner (Figure 3). 
Three potent synthetic compounds, 48, 45, and 50, were also effective (Figure 4), while the 
most potent antiproliferative compound, 46, maintained this low-dose efficacy in the tube 
formation assay (Figure 5). 
CONCLUSIONS 
A group of naturally occurring homoisoflavonoids isolated from the Hyacinthaceae as well as 
compounds synthesized have been tested for their antiangiogenic activities. The most potent 
compounds, 13, 28, 29, 42, 43, 45, 46, 48 and the chalcone 50, demonstrated selective 
antiproliferative activities on endothelial cells compared to non-endothelial cell types, with 
concentration-dependent antiangiogenic effects in vitro on HRECs, a disease-relevant cell type. 
Recently, intracellular target proteins for some other bioactive homoisoflavonoids have been 
identified: ferrochelatase as a target of cremastranone,44 soluble epoxide hydrolase as a target 
of SH-11037 (a synthetic Boc-Phe-derivatized homoisoflavonoid),45 and inosine 
monophosphate dehydrogenase 2 as a target of sappanone A.46 The relative effects of the 
natural products described here on each of these enzymes will be a valuable topic for future 
exploration. Our results will open the doors to the development of further synthetic analogues 
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with higher potency and better antiangiogenic activities to treat blinding eye diseases caused 
by pathological neovascularization. 
 
EXPERIMENTAL SECTION 
General Experimental Procedures. 
NMR spectra were recorded on a 500MHz Bruker AVANCE NMR instrument in either CDCl3 
or CD3OD at room temperature.  All chemical shifts ) are in ppm and referenced to the 
relevant solvent references, 7.26 ppm (CDCl3) and 4.87 ppm (CD3OD) for 
1H NMR spectra 
and 77.23 ppm (CDCl3) and 49.15 ppm (CD3OD) for 
13C NMR spectra. ESI mass spectra were 
either recorded on a Bruker MicroToF mass spectrometer using an Agilent 1100 HPLC to 
introduce samples (University of Oxford), a Micromass Quattro Ultima mass spectrometer 
using a Waters Alliance HPLC to introduce samples (University of Surrey) or a Waters Xevo 
G2-S (National Mass Spectrometry Facility, Swansea). Optical rotations were recorded in 
CDCl3 on a JASCO P-1020 polarimeter (University of Surrey), IR spectra were recorded on a 
Perkin-Elmer 2000 spectrometer (University of Surrey), and UV spectra were recorded using 
a Biochrom libraS60 in MeOH or acetonitrile in a 1 cm cell (University of Surrey).  CD spectra 
were recorded using a Chirascan spectropolarimeter at room temperature in a 1cm cell in 
MeOH (University of Surrey).  Reagents were purchased from Sigma-Aldrich Company Ltd, 
Gillingham, UK, SP8 4XT and used without further purification. 
Plant Material. 
The sourcing of plant material, extraction methodology and isolation of compounds from the 
bulbs of L. ovatifolia (Bak.) Jessop, L socialis (Bak.) Jessop, Rhodocodon campanulatus 
Knirsch, Mart Azoriń & Wetschnig and Rhodocodon aff. intermedius have been described 
before.24,25 Bulbs of Chinodoxa. luciliae Boiss. (Gigantea Hort), Eucomis autumnalis (Mill.) 
Chitt. and E. bicolor Baker were purchased from the Dix Export Company (Netherlands) in 
2012 and grown to produce a flowering specimen to confirm identification. Voucher specimens 
(DAM 2012 CL, EA and EB) are retained at the University of Surrey.  
 
Extraction and Isolation. 
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Dried bulbs of Chinodoxa luciliae (3.0 kg) were extracted in EtOH at room temperature for 24 
hours on a shaker. The resulting extract (119 g) was separated using gravity column 
chromatography over silica gel (Merck 9385) and solvent mixtures of 80:20 CH2Cl2:EtOAc 
(75 cm-3, 75 fractions) and 70:30 CH2Cl2:EtOAc (75 cm
-3, 10 fractions). Further purification 
was necessary in some cases using PTLC (Macherey-Nagel 0.25 mm, silica gel 60 with 
fluorescent indicator UV254), further column chromatography or acetylation of complex 
mixtures to obtain pure compounds. Fraction 68 yielded 15 (11 mg), fraction 70 yielded, after 
further purification, 16 (2 mg) and 17 (10 mg), fraction 72 yielded 18 (17 mg) and after 
acetylation of a mixture containing 17, the monoacetate, 19 (15 mg) and diacetate (12 mg), 20. 
Fraction 74 yielded, after further purification, 21 (20 mg) and 22 (20 mg), Fraction 77 yielded 
23 (50 mg) and fraction 80 yielded 24 (15 mg).  Compounds were identified using 2D NMR 
and CD methods and by comparison against literature data as referenced earlier.  
Chopped bulbs of E. autumnalis (4 kg) were extracted with MeOH (3 L) for 48 hours yielding 
an extract which was partitioned with CH2Cl2 (300 ml) to yield extract 1 (5.1 g) after solvent 
evaporation.  Bulb material was further extracted in 1-butanol (2.5 L) for 24 hours, yielding 
extract 2 (26.9 g) after solvent evaporation.  Extract 1 was separated using gravity column 
chromatography over silica gel (Merck 9385) and a gradient solvent elution method, (40 cm-3, 
63 fractions) using solvent mixtures of 50:50 hexane:CH2Cl2 (40 cm
-3, 6 fractions), 20:80 
hexane:CH2Cl2 (40 cm
-3, 9 fractions), 100% CH2Cl2 (40 cm
-3, 4 fractions), 50:50 
CH2Cl2:EtOAc (40 cm
-3, 27 fractions), 50:50 CH2Cl2:MeOH (20 cm
-3, 17 fractions).  Fraction 
24 yielded, after further purification, 30 (3.5 mg), Fractions 26-7 yielded, after further 
purification 31 (139.5 mg) and 32 (1.9 mg).  Fractions 34-38 yielded, after further purification 
22 (101 mg), Fractions 41-43 yielded, after further purification 33 (15.7 mg) and 34 (7.1 mg).  
Fraction 45 yielded, after further purification the previously unreported compound 35 (37.5 
mg). Red-brown oil; [α]27D -55.6 (c 0.03, CH3OH); ECD (c 0.03, MeOH) 290 nm (-5), 230 nm 
(−2); IR (NaCl) νmax 3327, 3007, 2938, 2400, 2000 1668 cm-1;1H NMR (CDCl3, 500 MHz), 
13C NMR (CDCl3, 125 MHz) Table 3; HRESIMS m/z 347.1125 [M + H]
+ (calcd for [C18H18O7 
+ H+, 347.1130) 
Extract 2 was separated using gravity column chromatography over silica gel (Merck 9385) 
and a gradient solvent elution method, (40 cm-3, 54 fractions) using solvent mixtures of 100% 
CH2Cl2 (40 cm
-3, 20 fractions), 50:50 CH2Cl2:EtOAc (40 cm
-3, 20 fractions), 50:50 
CH2Cl2:MeOH (20 cm
-3, 14 fractions).  Fractions 5-11 yielded after further purification 36 (1.5 
mg). Fractions 31-33 yielded, after further purification, 37 (1.2 mg), 38 (6.4 mg) and 39 (1.2 
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mg).  Compounds were identified using 2D NMR and CD methods and by comparison against 
literature data as referenced earlier.       
Bulbs of E. bicolor (5 kg) were chopped and extracted EtOH (3 L) for 48 hours. The EtOH 
extract was partitioned with CH2Cl2 (300 ml) yielding Extract 3 (12.7 g) after evaporation of 
the CH2Cl2 and the remaining EtOH extract, Extract 4 (12.0 g). The bulbs were re-extracted in 
1-butanol (2.5 L) for 24 hours, yielding Extract 5 (14.8 g) after solvent evaporation.  Extract 3 
(12.7 g) was coated onto silica, loaded into a column and separated using flash column 
chromatography using a gradient solvent elution method, (20 cm-3, 282 fractions) using solvent 
mixtures of 100% hexane (20 cm-3, 50 fractions), 50:50 hexane:CH2Cl2 (20 cm
-3, 50 fractions), 
100% CH2Cl2 (20 cm
-3, 50 fractions), 50:50 CH2Cl2:EtOAc (20 cm
-3, 100 fractions), 50:50 
CH2Cl2:MeOH (20 cm
-3, 32 fractions) Fractions 160-170 yielded 40 (193.8 mg), Fractions 224-
225 yielded 41 (321.9 mg).  Extract 4 (12.0 g) was separated using gravity column 
chromatography over silica gel (Merck 9385) and a solvent mixture of 80:20 CH2Cl2:EtOAc 
(100 cm-3, 9 fractions).  Fraction 2 yielded 40 (60.5 mg), fractions 4-6 yielded 41 (322.7 mg).  
Extract 5 (14.8 g) was separated using gravity column chromatography over Sephadex using a 
solvent mixture of 50:50 50:50 CH2Cl2:MeOH (150 cm
-3, 6 fractions).  Fractions 5-6 yielded, 
after further purification 41 (186.7 mg) and 32 (28.2 mg).  Compounds were identified using 
2D NMR and CD methods and by comparison against literature data as referenced earlier. 
Synthesis of Compounds 42 – 50.  
Preparation of (E)-5,7-dimethoxy-3-(4ʹ-methylthiobenzylidene)-4-chromanone (42):  
Under inert conditions, NaH (60% in mineral oil, 13 mmol) was added to 3,5-dimethoxyphenol 
(1g, 6 mmol) in dry DMF (10 mL) at 10oC.  After stirring for 60 minutes, 3-bromopropionic 
acid (1.1 g, 7.2 mmol) was added and the reaction was further stirred at room temperature for 
60 minutes.  The mixture was acidified with HCl to pH 3-5, extracted into EtOAc and washed 
with brine (1 x 30 mL) and water (1 x 30 mL).  The product (3-(3,5-dimethoxyphenoxy)-
propanoic acid) was used without further purification. 
Polyphosphoric acid (10g) was added to 3-(3,5-dimethoxyphenoxy)-propanoic acid and the 
resulting mixture was heated at 80oC for 2 hours.  The mixture was poured into ice water and 
extracted into diethyl ether.  The extract was washed with 3N NaOH (30 mL), water (50 mL) 
and dried over MgSO4.  The product (3,5-dimethoxychromone) was heated at 80
oC with 4-
methylthiobenzaldehyde (1:1 molar equivalent) and piperidine (4-5 drops) and the reaction was 
monitored by tlc (3:7, EtOAc:n-hexane).  The mixture was diluted with water and extracted 
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into EtOAc.  This was washed with water (30 mL) and brine (30 mL), before drying over 
MgSO4.  The resulting product was purified by flash column chromatography (3:7, EtOAc:n-
hexane) to give (E)-5,7-dimethoxy-3-(4ʹ-methylthiobenzylidene)-4-chromanone (42) as a 
yellow gum (61 mg, 3.0% overall yield). 
 UV (MeOH) max(log ) 346 (-3.78); IR (ATR) νmax 1659, 1583,1495, 1463, 1343, 1198, 1093, 
830 cm−1; 1H NMR (CDCl3, 400 MHz) Table 4; 
13C NMR (CDCl3, 100 MHz) Table 5; 
HRESIMS m/z 343.0989 [M + H]+ (calcd for [C19H18O4SH + H]
+, 343.0999) 
 
Preparation of (E)-7,8-dimethoxy-3-(4ʹ-methylthiobenzylidene)-4-chromanone (43):  
Under inert conditions, NaH (60% in mineral oil, 13 mmol) was added to 2,3-dimethoxyphenol 
(1g, 6 mmol) in dry DMF (10 mL) at 10oC.  After stirring for 60 minutes, 3-bromopropionic 
acid (1.1 g, 7.2 mmol) was added and the reaction was further stirred at room temperature for 
60 minutes.  The mixture was acidified with HCl to pH 3-5, extracted into EtOAc and washed 
with brine (1 x 30 mL) and water (1 x 30 mL).  The product (3-(2,3-dimethoxyphenoxy)-
propanoic acid) was used without further purification. 
Polyphosphoric acid (10g) was added to 3-(2,3-dimethoxyphenoxy)-propanoic acid (from 
above) and the resulting mixture was heated at 80oC for 2 hours.  The mixture was poured into 
ice water and extracted into diethyl ether.  The extract was washed with 3N NaOH (30 mL), 
water (50 mL) and dried over magnesium sulphate.  The product (2,3-dimethoxychromone) 
was heated at 80oC with 4-methylthiobenzaldehyde (1:1 molar equivalent) and piperidine (4-5 
drops) and the reaction was monitored by tlc (3:7, EtOAc:n-hexane).  The mixture was diluted 
with water and extracted into EtOAc, washed with water (30 mL) and brine (30 mL), before 
drying over MgSO4.  The product was purified by flash column chromatography (3:7, 
EtOAc:n-hexane) to give (E)-7,8-dimethoxy-3-(4ʹ-methylthiobenzylidene)-4-chromanone (43) 
as a yellow gum (72 mg, 3.5% overall yield). 
UV (MeOH)max(log ) 343 (-4.02); IR (NaCl) νmax 2921, 1665, 1580, 1572, 1493, 1425, 1306, 
1264, 1159, 820 cm−1;1H NMR (CDCl3, 400 MHz) Table 4; 
13C NMR (CDCl3, 100 MHz) 
Table 5; HRESIMS m/z 343.0995 [M + H]+ (calcd for [C19H18O4SH + H]
+, 343.0999) 
 
Preparation of (E)-5,6,7-trimethoxy-3-(3ʹ-hydroxy-4ʹ-methoxybenzylidene)-4-chromanone 
(44):  
Under inert conditions, NaH (60% in mineral oil, 13 mmol) was added to 3,4,5-
trimethoxyphenol (1 g, 5.4 mmol) in dry DMF (10 mL) at 10oC.  After stirring for 60 minutes, 
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3-bromopropionic acid (1.1 g, 7.2 mmol) was added and the reaction was further stirred at 
room temperature for 60 minutes.  The mixture was diluted with methanol (20 ml) acidified 
with HCl to pH 3-5, extracted into EtOAc and washed with brine (1 x 30 mL) and water (1 x 
30 mL).  The product (3-(3,4,5-trimethoxyphenoxy)-propanoic acid) was used without further 
purification. 
Polyphosphoric acid (10 g) was added to 3-(3,4,5-trimethoxyphenoxy)-propanoic acid (from 
above) and the resulting mixture was heated at 80oC for 2 hours.  The mixture was poured into 
ice water and extracted into diethyl ether.  The extract was washed with 3M NaOH (30 mL), 
water (50 mL) and dried over MgSO4.  The product (3,4,5-trimethoxychromone) was heated at 
80oC with 3-hydroxy-4-methoxybenzaldehyde (1:1 molar equivalent) and piperidine (4-5 
drops) and the reaction was monitored by tlc (3:7, EtOAc:n-hexane).  The mixture was diluted 
with water and extracted into EtOAc, washed with water (30 mL) and brine (30 mL), before 
drying over MgSO4.  The resultant product was purified by flash column chromatography (3:7, 
EtOAc:n-hexane) to give (E)-5,6,7-trimethoxy-3-(3ʹ-hydroxy-4ʹ-methoxybenzylidene)-4-
chromanone (44) as a yellow gum (0.1053 g, 5.2% yield). 
UV (MeOH) max(log ) 360 (-3.77), 348 (-3.76), IR νmax (NaCl) 3650-3590,  3376, 2936, 2841, 
1596 cm-1; 1H NMR (CDCl3, 400 MHz) Table 4; 
13C NMR (CDCl3, 100 MHz) Table 5; 
HRESIMS m/z 395.1096 [M + Na]+ (calcd for [C20H20O7 + Na]
+, 395.1107) 
 
Preparation of 5,6,7-trimethoxy-3(R)-(3ʹhydroxy-4ʹ-methoxybenzyl)-4-chromanone (45): 
Compound 44 (34.6mg, 0.093mmol) was dissolved in deuterated toluene (1 mL). Iridium 
catalyst 1, (S)-(-)-2-[2-(diphenylphosphino)phenyl]-4-isopropyl-2-oxazolium-(1,5)-
cyclooctadiene iridium (I) tetrakis(3,5-bis(trifluoromethyl)phenyl borate (Scheme 2) was 
added (1%) and the reactor was pressurised to 5 bar with hydrogen.  The reaction was stirred 
overnight at room temperature.  The mixture was filtered to remove the catalyst and the NMR 
data were obtained directly in deuterated toluene (quantitative yield). 
Yellow gum; [α]23D -43.8 (c 0.9, CH3OH); ECD (c 0.03, ACN) 326 nm (+1.3), 284 nm (−1.9) 
UV (MeOH) max (log ) 277 (-4.20), 277 (-3.66); IR (NaCl) νmax 2936, 1674, 1580, 1567, 
1485, 1454, 1412, 1200, 1179, 1116, 822 cm−1;1H NMR (CDCl3, 400 MHz) Table 4; 
13C NMR 
(CDCl3, 100 MHz) Table 5; HRESIMS m/z 397.1259 [M + Na]
+ (calcd for [C20H22O7 + Na]
+, 
397.1263) 
 
Preparation of 5,6,7-trimethoxy-3-(3ʹhydroxy-4ʹ-methoxybenzyl)-chromane (46):  
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Compound 44 (50.0 mg, 0.134 mmol) was dissolved in methanol (2 mL).  Pd/C (10%) was 
added, the flask was saturated with H2 (1 atmosphere) and the mixture was stirred overnight at 
room temperature.  The catalyst was filtered and the solvent removed under reduced pressure 
to yield 46 (quantitative yield). 
Yellow gum; UV (MeOH) max (log ) 282 (-3.14); 1H NMR (CDCl3, 400 MHz) Table 4; 13C 
NMR (CDCl3, 100 MHz) Table 5; HRESIMS m/z 383.1462 [M + Na]
+ (calcd for [C20H24O6 + 
Na]+,383.1471) 
 
Preparation of 5,6,7-trimethoxy-3-(3ʹhydroxy-4ʹ-methoxybenzyl)-4-chromanone (47): 
Compound 44 (5.9 mg, 0.0158 mmol) was dissolved in toluene (2 mL).  Wilkinson’s catalyst 
(1%) was added, the flask was saturated with H2 (1 atmosphere) and the mixture was stirred 
overnight at room temperature.  The catalyst was filtered and the solvent removed under 
reduced pressure.  The mixture obtained was subject to column chromatography over silica gel 
(8:2 EtOAc:CH2Cl2) to yield 47 (2.4 mg, 40% yield). Yellow gum; UV (MeOH) max (log ) 
278 (-3.02); 1H NMR (CDCl3, 400 MHz) Table 4; HRESIMS m/z 397.1254 [M + Na]
+ (calcd 
for [C20H22O7 + Na]
+, 397.1263). 
 
Preparation of (E)-5-hydroxy-6,7-trimethoxy-3-(3ʹhydroxy-4ʹ-methoxybenzylidene)-4-
chromanone (48):  
Compound 44 (7.9 mg, 0.021 mmol) was dissolved in dry CH2Cl2 (2 mL) and cooled to 0
oC.  
TMSCl (8 equivalents) and NaI (8 equivalents) were added and the mixture was heated to 60oC 
for 2 hours.  The solvent was removed under reduced pressure and the product purified using 
column chromatography over silica gel (2:8, EtOAc: CH2Cl2) to give 5-hydroxy-6,7-
trimethoxy-3-(3ʹhydroxy-4ʹ-methoxybenzylidene)-4-chromanone (48) (4.5 mg, 60% yield). 
Yellow gum; UV (MeOH) max (log ) 368 (-4.03); IR (NaCl) νmax 3525, 2935, 2848, 1643, 
1579, 1511, 1455, 1359, 1272, 1202, 1106, 813, 736 cm−1; 1H NMR (CDCl3, 400 MHz) Table 
4; 13C NMR (CDCl3, 100 MHz) Table 5; HRESIMS m/z 381.0946 [M + Na]
+ (calcd for 
[C19H18O7 + Na]
+, 381.0950). 
 
Preparation of (E)-5,6,7-trimethoxy-3-(4ʹ- chloro-3ʹ- hydroxybenzylidene)-4-chromanone 
(49):  
NaH (60% in mineral oil, 13 mmol) was added to 3,4,5-trimethoxyphenol (1 g, 5.4 mmol) in 
dry DMF (10 mL) at 10oC under inert conditions.  After stirring for 60 minutes, 3-
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bromopropionic acid (1.1 g, 7.2 mmol) was added and the reaction was stirred at room 
temperature for a further 60 minutes.  The mixture was acidified with HCl to pH 3-5, extracted 
into EtOAc and washed with brine (1 x 30 mL) and water (1 x 30 mL).  The product (3-(3,4,5-
trimethoxyphenoxy)-propanoic acid) was used without further purification. 
Polyphosphoric acid (10 g) was added to 3-(3,4,5-trimethoxyphenoxy)-propanoic acid (from 
above) and the resulting mixture was heated at 80oC for 2 hours.  The mixture was poured into 
ice water and extracted with diethyl ether.  The extract was washed with 3M NaOH (30 mL), 
water (50 mL) and dried over magnesium sulphate.  The product (3,4,5-trimethoxychromone) 
was heated at 80oC with 4-chloro-3-hydroxybenzaldehyde (1:1 molar equivalent) and 
piperidine (4-5 drops) and the reaction was monitored by tlc (3:7, EtOAc:n-hexane) and was 
found to be complete after 24 hours.  The mixture was diluted with water and extracted into 
EtOAc, then washed with water (30 mL) and brine (30 mL), before drying over MgSO4.  The 
product was purified by flash column chromatography (3:7, EtOAc:n-hexane) to give 5,6,7-
trimethoxy-3-(4ʹ-chloro-3ʹ- hydroxybenzylidene)-4-chromanone (49) as a yellow powder (155  
mg, 7.8% yield). 
UV (MeOH) max (log ) 295 (-3.94), 352 (-3.77); IR (NaCl) νmax 3328, 2939, 1661, 1650, 
1488, 1470, 1415, 1391, 1258, 1201, 1171, 1100, 818 cm−1; 1H NMR (CDCl3, 400 MHz) Table 
4; 13C NMR (CDCl3, 100 MHz) Table 5; HRESIMS m/z 377.0786 [M + H]
+ [calcd for 
(C19H17O6Cl + H)
+,377.0792]. 
 
Preparation of (E)-3-(3,4-dimethoxylphenyl)-1-(4-ethoxy-2-hydroxy-3-methyl-phenyl)prop-2-
en-1-one (50):  
4-Ethoxy-2-hydroxy-3-methyl acetophenone (0.1 g, 0.51 mmol) was added to 3,4-
dimethoxybenzaldehyde (0.85 g, 0.51 mmol) and 10% NaOH (1 mL) in methanol (5 ml) and 
stirred at room temperature for 2 hours.  Upon standing, (E)-3-(3,4-dimethoxylphenyl)-1-(4-
ethoxy-2-hydroxy-3-methyl-phenyl)prop-2-en-1-one (50) precipitated out as a yellow powder 
and was isolated by vacuum filtration (25.9 mg, 15% yield). 
UV (MeOH)max (log ) 368 (-4.62); IR (ATR) νmax 1650, 1570,1550, 1499, 1419, 1364, 1265, 
1221, 1080, 847 cm−1;1H NMR (CDCl3, 400 MHz) Table 4; 
13C NMR (CDCl3, 100 MHz) 
Table 5; HRESIMS m/z 343.1545 [M + H]+ [calcd for (C20H22O5+ H)
+, 343.1545]. 
 
Biological Methods 
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Materials 
Human retinal microvascular endothelial cells (HRECs; Cell Systems, Seattle, WA) and human 
umbilical vein endothelial cells (HUVECs; Lonza, Walkersville, MD), were used between 
passage 5 and 8. Endothelial Growth Medium (EGM-2) was prepared by mixing the contents 
of an EGM-2 “Bullet Kit” (Cat no. CC-4147) with Endothelial Basal Medium (EBM) (Cat no. 
CC-3156) (Lonza). 92-1 uveal melanoma cells (a kind gift of Dr. Martine Jager, University of 
Leiden) were grown in RPMI medium containing 10% FBS and 1% penicillin-streptomycin 
(pen-strep). Y-79 retinoblastoma cells (a kind gift of Dr. Brenda L. Gallie, Ontario Cancer 
Institute) were grown in RB medium (IMDM + 10% FBS + 55 μM β-mercaptoethanol + 10 
μg/mL Insulin + 1% pen-strep). ARPE-19 retinal pigment epithelial cells (ATCC, Manassas, 
VA) were grown in DMEM containing 10% FBS and 1% pen-strep. AlamarBlue reagent 
(product code BUF012B) was from AbD Serotec (Raleigh, NC). Matrigel matrix basement 
membrane (Cat no.354234) was purchased from Corning (Corning, NY) 
 
Cell proliferation assay  
The antiproliferative activities of different compounds were monitored by an alamarBlue based 
fluorescence assay as described previously.43
 
Five cell types were used: the target endothelial 
cell type (HRECs), a non-target endothelial cell type (HUVECs), a non-target normal retinal 
pigment epithelial cell line (ARPE-19), a non-target uveal melanoma cell line (92-1), and a 
non-target retinoblastoma cell line (Y79). Briefly, 2,500 cells in 100 μL growth medium were 
incubated in 96-well clear bottom black plates for 24 hours at 37°C, 5% CO2, different 
concentrations of each test compound were then added (range: 0.5 nM to 500 μM) followed by 
44 hours incubation. 11.1 μL of alamarBlue reagent was then added and after 4 hours, 
fluorescence readings were taken on a Synergy H1 plate reader (Biotek, Winooski, VT) with 
excitation and emission wavelengths of 560 nm and 590 nm respectively. GraphPad Prism 
software (v. 7.0) was used for data analysis. Compounds that reduced cell number by 50% or 
more at the highest concentration tested (relative to DMSO control) were reported as having a 
GI50 < 100μM.  
In vitro tube formation assay  
A Matrigel based tube formation assay was performed to monitor the ability of HRECs to form 
tube-like structures in the presence of different concentrations of 13, 27, 28, 45, 46, 48 and 50, 
as described previously.20
 
Briefly, 15,000 cells in 100 μL EGM-2 medium were incubated in 
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the absence (DMSO treated) and presence of different concentrations of each compound in 96-
well clear plates coated with 50 μL of Matrigel basement membrane. Known antiangiogenic 
homoisoflavonoid SH-1103721 was a positive control. After 8 hours, the images were recorded 
using an EVOS FL microscope (AMG, Mill Creek, WA) and the tube length was measured 
using Angiogenesis Analyzer macros in ImageJ 
(http://image.bio.methods.free.fr/ImageJ/?Angiogenesis-Analyzer-for- ImageJ).  
Statistical analysis  
The data obtained from tube formation experiments were analyzed by one-way ANOVA with 
Dunnett’s post hoc tests for comparisons between compounds’ treatments and control. All 
analyses were performed using GraphPad Prism software (v.7.0). A p value of <0.05 was 
considered statistically significant.  
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Tables 
Table 1. Antiproliferative activity of homoisoflavonoids and co-isolated compounds against endothelial and ocular tumour cells (growth 
inhibitory concentration, GI50, shown in µM). ND, no data. 
No. Structure Source 
GI50 
HRE
C 
GI50 
HUV
EC 
GI50 
92-1 
GI50 
Y79 
No. Structure Source 
GI50 
HREC 
GI50 
HUV
EC 
GI50 
92-1 
GI50 
Y79 
1 
 
Ledebouria 
socialis 
>100 >100 >100 >100 16 
 
Chionodoxa 
luciliae 
>100 >100 >100 >100 
2 
 
Ledebouria 
socialis 
>100 >100 >100 >100 17 
 
Chionodoxa 
luciliae 
>100 >100 >100 >100 
3 
 
Ledebouria 
ovatifolia 
>100 >100 ND >100 18 
 
Chionodoxa 
luciliae 
>100 >100 >100 >100 
4 
 
Ledebouria 
ovatifolia 
>100 >100 >100 >100 19 
 
Chionodoxa 
luciliae 
>100 >100 >100 >100 
5 
 
Ledebouria 
ovatifolia 
>100 >100 >100 >100 
20 
 
 
Chionodoxa 
luciliae 
>100 >100 >100 >100 
24 
 
6 
 
Ledebouria 
ovatifolia 
>100 >100 >100 >100 21 
 
Chionodoxa 
luciliae 
>100 >100 >100 >100 
7 
 
Ledebouria 
ovatifolia 
>100 >100 >100 >100 
22 
 
 
Chionodoxa 
luciliae 
Eucomis 
autumnalis 
>100 >100 >100 >100 
8 
 
Ledebouria 
ovatifolia 
>100 >100 >100 >100 23 
 
Chionodoxa 
luciliae 
>100 >100 >100 >100 
9 
 
Ledebouria 
ovatifolia 
>100 >100 >100 >100 24 
 
Chionodoxa 
luciliae 
40 >100 >100 >100 
10 
 
Ledebouria 
ovatifolia 
 
>100 14 >100 25 
25 
 
 
Rhodocodon 
campanulatus 
>100 >100 >100 >100 
11 
 
Ledebouria 
ovatifolia 
>100 >100 >100 >100 26 
 
Rhodocodon 
campanulatus 
>100 92 >100 >100 
12 
 
Ledebouria 
ovatifolia 
>100 >100 >100 >100 27 
 
Rhodocodon 
aff. 
intermedius 
16 11 69 29 
25 
 
13 
 
Ledebouria 
ovatifolia 
1.4 5.0 >100 2.5 28 
 
Rhodocodon 
aff. 
intermedius 
18 26 67 58 
14 
 
Ledebouria 
ovatifolia 
96 43 >100 >100 
29 
 
 
Rhodocodon 
aff. 
intermedius 
17 41 >100 23 
15 
 
Chionodoxa 
luciliae 
>100 >100 >100 >100 
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Table 2. Antiproliferative activity of natural-source and synthetic homoisoflavonoids and co-isolated compounds against HRECs and 
other ocular cell types (growth inhibitory concentration, GI50, shown in µM). 
No. Structure Source 
GI50 
HRE
C 
GI50 
ARP
E-19 
GI50 
92-1 
GI50 
Y79 
No. Structure Source 
GI50 
HREC 
GI50 
ARP
E-19 
GI50 
92-1 
GI50 
Y79 
30 
 
Eucomis 
autumnalis 
>100 >100 >100 >100 41 
 
Eucomis 
bicolor 
74 >100 >100 >100 
31 
 
Eucomis 
autumnalis 
12 83 >100 >100 42 
 
synthetic 2.5 48 >100 2 
32 
 
Eucomis 
autumnalis 
Eucomis 
bicolor 
>100 >100 >100 >100 43 
 
synthetic 3.6 >100 >100 11 
33 
 
Eucomis 
autumnalis 
64 >100 >100 >100 44 
 
synthetic 2.2 1.3 8.2 23 
34 
 
Eucomis 
autumnalis 
60 >100 >100 >100 45 
 
synthetic 0.035 >100 >100 85 
35 
 
Eucomis 
autumnalis 
 
>100 >100 >100 >100 46 
 
synthetic 
2.3 
x10-4 
3.4 
x10-4 
52 18 
27 
 
36 
 
Eucomis 
autumnalis 
>100 >100 >100 >100 47 
 
synthetic 0.21 >100 >100 >100 
37 
 
Eucomis 
autumnalis 
>100 >100 >100 >100 48 
 
synthetic 0.26 4.8 >100 2.4 
38 
 
Eucomis 
autumnalis 
>100 >100 >100 >100 49 
 
synthetic 0.11 0.73 3.6 13 
39 
 
Eucomis 
autumnalis 
>100 >100 >100 >100 50 
 
synthetic 3.9 >100 >100 >100 
40 
 
Eucomis 
bicolor 
64 >100 >100 >100 
 
 
 
 
 
 
 
Table 3. NMR data (1H 500 MHz, 13C 125 MHz) for compound 35 (in CDCl3, J in Hz). 
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Table 4. 1H NMR (400 MHz) Data for Compounds 42 - 50 (in CDCl3, J in Hz) 
Position 1H  13C 
2 (α) 4.37 (dd, 11.4, 4.1) 69.9, CH2 
(β) 4.20 (dd, 11.4, 7.2)  
3 2.79 m 49.3, CH 
4  192.0, C 
4a  110.0, C 
5  139.5, C 
6  137.2, C 
7  140.6, C 
8  134.1, C 
8a  143.3, C 
9 (a) 3.17 (dd, 14.0 4.4) 32.2, CH2 
(b) 2.70 (dd, 14.0, 10.6)  
1ʹ  130.5 C 
2ʹ 7.11 (d, 8.1) 130.6 CH 
3ʹ 6.79 (d, 8.1) 115.8 CH 
4ʹ  154.6 C 
5ʹ 6.79 (d, 8.1) 115.8 CH 
6ʹ 7.11 (d, 8.1) 130.6 CH 
5-OCH3 3.88 s 62.3 
6-OH 5.59 br s  
7-OCH3 4.11 s 61.3 
8-OH 5.39 br s  
4ʹ-OH 4.74 s  
29 
 
position 42 43 44 45 46 47 48 49 50 
2 5.17, d (2.0)  5.34, d (1.8) 5.21, bs 4.04, dd 
(7.6, 11.4) 
4.21, dd 
(4.1, 11.4) 
3.65, dd (3.1, 
10.7) 
4.02, dd 
(10.1, 10.7) 
4.09, dd (7.6, 
11.4) 
4.27, dd (4.1, 
11.4) 
5.25, d (1.8) 4.99, d 
(1.8) 
7.47, d 
(15.2) 
3    2.68, m 2.14, m 2.74, m   7.84, d 
(15.2) 
4     2.53, dd (4.1, 
7.4) 
    
5  7.75, d (8.8)        
OH-5       12.45, s  13.51 
6 6.05, d (2.3) 6.63, d (8.8)        
8 6.00, d (2.3)  6.22, s 6.17, s 6.11, s 6.25, s 5.98, s 6.16, s 6.48, d (9.5)  
7.78, d (9.5) 
9 7.69, bs  
 
7.74, bs 7.71, s 2.54, dd 
(10.4, 14.5) 
3.12, dd 
(4.0, 14.5) 
2.25, dd (7.6, 
16.2) 
2.70, ddd 
(1.5, 5.4, 
16.2) 
2.58, dd 
(10.4, 14.5) 
3.18, dd (4.0, 
14.5) 
7.70, bs 7.75, bs  
2ʹ 7.12, d (7.8) 7.18, d (8.5) 6.84, dd 
(2.0, 8.4) 
6.62, dd 
(2.0, 8.3) 
6.58, dd (2.1, 
8.4) 
6.70, dd (2.0, 
8.3) 
6.79, dd 
(1.9, 7.9) 
7.15, dd 
(2.4, 8.6) 
7.25, dd 
(1.9, 8.4) 
6ʹ 7.12, d (7.8) 7.18, d (8.5) 6.79, d (2.0) 6.73, d (2.0) 6.72, d (2.1) 6.81, d (2.0) 6.81, d (1.9) 6.91, d 
(2.4) 
7.16, d (1.9) 
3ʹ 7.20, d (7.8) 7.20, d (8.5) 6.86, d (8.4) 6.71, d (8.3) 6.71, d (8.4) 6.79, d (8.3) 6.85, d (7.9) 6.83, d 
(8.6) 
6.91, d (8.4) 
5ʹ 7.20, d (7.8) 7.20, d (8.5)        
SCH3-4ʹ 2.45, s 2.46, s        
OCH3 3.76, s 
3.84, s 
3.79, s 
3.87, s 
3.80 
3.85 
3.88 
3.95 
3.79, s 
3.86, s 
3.86, s 
3.99, s 
3.72, s 
3.72, s 
3.78, s 
3.81, s 
3.81, s 
3.88, s 
3.88, s 
3.93, s 
3.78, s 
3.82, s 
3.89, s 
 
3.75, s 
3.82, s 
3.91, s 
 
3.94, s 
3.96, s 
CH3         2.15, s 
30 
 
CH2CH3         4.13, q (7.1) 
CH2CH3         1.47, t (7.1) 
31 
 
Table 5. 13C NMR (100 MHz) Data for Compounds 42 – 46 and 48 - 50 (in CDCl3) 
position 42 43 44 45 46 48 49 50 
2 67.6, CH2 68.2, CH2 67.8, CH2 69.1, CH2 69.6, CH2 67.4, CH2 67.2, CH2 118.4, CH 
3 131.4, C 130.3, C 130.2, C 48.3, CH 33.2, CH 127.8, C 129.9, C 144.2, CH 
4 179.4, C 181.2, C 179.8, C 191.4, C 37.5, CH2 185.8, C 179.7, C 192.3, C 
4a 162.8, C 158.4, C 154.8, C 154.4, C 107.2, C 155.9, C 159.7, C 163.2, C 
5 164.5, C 124.0, CH 159.3, C 159.5, C 132.7, C 160.8, C 154.9, C 162.5, C 
6 93.6, CH 106.1, CH 147.9, C 154.7, C 151.6, C 130.7, C 153.3, C 114.0, C 
7 107.3,C 117.3, C 137.9, C 137.8, C 135.8, C 156.6, C 138.3, C 162.9, C 
8 93.5, CH 136.6, C 96.3, CH 96.0, CH 96.2, CH 91.9, CH 96.5, CH 102.5, CH 
8a 165.7, C 154.7, C 159.5, C 159.2, C 152.2, C 158.1, C 159.9, C 128.9, CH 
9 136.3, CH 136.3, CH 136.5, CH 32.2, CH2 25.5, CH2 138.1, CH 129.8, CH - 
1ʹ 131.3, C 129.1, C 128.1, C 131.6, C 132.7, C 127.6, C 133.4, C 127.5, C 
2ʹ 131.3, CH 131.3, CH 123.3, CH 120.5, CH 120.4, CH 123.3, CH 130.4, CH 123.7, CH 
3ʹ 128.5, CH 128.5, CH 110.8, CH 110.8, CH 110.8, CH 110.7, CH 118.1, CH 111.3, CH 
4ʹ 140.5,C 140.5, C 147.9, C 145.6, C 152.3, C 145.9, C 125.3, C 148.6, C 
5ʹ 128.5, CH 128.5, CH 145.8, C 145.3, C 145.5, C 145.6, C 125.4, C 152.1, C 
6ʹ 131.3, CH 131.3, CH 116., CH 116.2, CH 115.4, CH 115.7, CH 129.2, CH 109.9, CH 
OCH3 57.0, CH3 56.2, CH3 56.1, CH3 56.0, CH3 55.8, CH3 56.1, CH3 56.1, CH3 56.1, CH3 
OCH3 56.4, CH3 61.2, CH3 56.2, CH3 56.1, CH3 56.0, CH3 56.2, CH3 61.2, CH3 56.1, CH3 
OCH3   61.4, CH3 61.3, CH3 60.6, CH3 60.9, CH3 61.6, CH3  
OCH3   61.7, CH3 61.6, CH3 61.0, CH3    
SCH3 15.3, CH3 15.2, CH3       
Ph-CH3        7.7, CH3 
CH2CH3        64.0, CH2 
CH2CH3        13.6, CH3 
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Figures 
 
Figure 1. HMBC correlations (H  C) for compound 35. 
 
Figure 2. Homoisoflavonoids block the proliferation of HRECs. Dose-response curves for 
representative active compounds’ effects on proliferation of the indicated cell types as 
assessed by alamarBlue fluorescence. Mean ± SEM, n=3–6 wells.  
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Figure 3. Potent natural-source homoisoflavonoids significantly block the ability of HRECs to 
form tube-like structures. Top, Representative images of the tube formation of HRECs on 
Matrigel at the highest concentrations of each compound tested plus DMSO control, scale bars 
= 250 μm. Bottom, Quantification of the extent of tube formation was measured as tubule 
length of HRECs treated with compounds compared to DMSO control. Mean ± SEM, n=3–6 
wells. Representative results from duplicate experiments. *P<0.05, ***P<0.001 compared to 
DMSO control (One-way ANOVA with Dunnett’s post-hoc tests). 
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Figure 4. Potent synthetic homoisoflavonoids significantly block the ability of HRECs to form 
tube-like structures. Top, Representative images of the tube formation of HRECs on Matrigel 
at the highest concentrations of each compound tested plus DMSO control, scale bars = 500 
μm. Bottom, Quantification of the extent of tube formation was measured as tubule length of 
HRECs treated with each compound compared to DMSO control. SH-11037 is a positive 
control. Mean ± SEM, n=6 wells. Representative results from duplicate experiments. *P<0.05, 
***P<0.001 compared to DMSO control (One-way ANOVA with Dunnett’s post-hoc tests). 
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Figure 5. Highly potent synthetic homoisoflavonoid 46 significantly blocks the ability of 
HRECs to form tube-like structures. Top, Representative images of the tube formation of 
HRECs on Matrigel, scale bars = 500 μm. Bottom, Quantification of the extent of tube 
formation was measured as tubule length of HRECs treated with compound compared to 
DMSO control. Mean ± SEM, n=6 wells. Representative results from duplicate experiments. 
***P<0.001 compared to DMSO control (One-way ANOVA with Dunnett’s post-hoc tests). 
 
 
 
 
 
 
 
 
36 
 
Schemes 
 
Scheme 1. General scheme for synthesis of 3-benzylidene homoisoflavonoids. 
 
Scheme 2. Reactions of Compound 44. (Iridium catalyst = (S)-(-)-2-[2-
(diphenylphosphino)phenyl]-4-isopropyl-2-oxazolium-(1,5)-cyclooctadiene iridium (I) 
tetrakis(3,5-bis(trifluoromethyl)phenyl borate).
37 
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 GI50 2.3 x 10
-4 µM   
(human retinal microvascular endothelial cells) 
 
 
 
